Mechanisms of Vaccine-induced Protective Immunity Against Coxiella Burnetii Infection in BALB/c Mice
Overview
Affiliations
To elucidate the mechanisms of vaccine-induced protective immunity against Coxiella burnetii infection, we compared the protective efficacy and immunogenicity between formalin-inactivated phase I vaccine (PI-V) and phase II vaccine (PII-V) in BALB/c mice. PI-V generated significant protection while PII-V did not confer measurable protection. Analysis of cytokine and subclass Ab responses indicated that both PI-V and PII-V were able to induce a Th1-dominant immune response but did not identify the component of host response that distinguished their ability to induce protective immunity. Interestingly, immunoblot analysis identified a difference between PI-V and PII-V vaccinates in antigenic recognition by specific Ab isotypes. The observation that PI-LPS elicited significant protection but PII-LPS did not confer measurable protection suggests PI-LPS may play a key role in PI-V-induced protection. Adoptive transfer of either immune sera or splenocytes mediated significant protection in naive BALB/c mice, supporting the notion that both humoral and cellular immunity are important for development of protective immunity. However, the evidence that immune sera and B cells were unable to control infection while T cells conferred significant protection in SCID mice supports the hypothesis that T cell-mediated immunity is critical for host defense against C. burnetii infection. This report presents novel evidence to highlight the importance of PI-LPS and Abs in protective immunity and has important implications for the design of new generation vaccines against Q fever.
Christodoulou M, Papagiannis D Vaccines (Basel). 2025; 13(2).
PMID: 40006698 PMC: 11861857. DOI: 10.3390/vaccines13020151.
Alam S, Kumaresan V, Palanisamy R, Zhang Y, Seshu J, Xiong N Front Immunol. 2024; 15:1427822.
PMID: 39469719 PMC: 11513344. DOI: 10.3389/fimmu.2024.1427822.
Molecular mechanisms of formalin-fixed cellular vaccine reactogenicity.
Fratzke A, Szule J, Butler S, Schaik E, Samuel J Infect Immun. 2024; 92(11):e0033524.
PMID: 39356158 PMC: 11556133. DOI: 10.1128/iai.00335-24.
Schaik E, Fratzke A, Gregory A, Dumaine J, Samuel J Front Cell Infect Microbiol. 2024; 14:1282183.
PMID: 38567021 PMC: 10985213. DOI: 10.3389/fcimb.2024.1282183.
Synthetic Particulate Subunit Vaccines for the Prevention of Q Fever.
Sam G, Plain K, Chen S, Islam A, Westman M, Marsh I Adv Healthc Mater. 2024; 13(7):e2302351.
PMID: 38198823 PMC: 11468694. DOI: 10.1002/adhm.202302351.